secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0000059478-25-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly updates 2024 revenue to ~$45B, Q4 ~$13.5B; guides 2025 revenue $58-61B
----------------------------------------------------------------------------

- 2024 full-year revenue expected ~$45.0B, up 32% YoY and $4B above initial guidance midpoint.
- Q4 2024 revenue ~$13.5B, up 45% YoY, but $400M below low end of Oct 30 guidance due to slower incretin growth and lower channel inventory.
- Mounjaro Q4 revenue ~$3.5B, Zepbound ~$1.9B; non-incretin revenue grew 20% YoY.
- 2025 revenue guidance $58-61B, midpoint growth of 32% vs expected 2024; includes new product launches and manufacturing expansion.
- Full Q4 2024 results and 2025 financial guidance to be reported on February 6, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947825000005/0000059478-25-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947825000005/lly-20250114.htm
  HTML page:      https://secwatch.observer/filing/0000059478-25-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer